Effects of Marital Status on Prognosis in Women with Infiltrating Ductal Carcinoma of the Breast: A Real-World 1: 1 Propensity-Matched Study

被引:6
|
作者
Lan, Tian [1 ]
Lu, Yunyan [2 ]
Luo, Hua [1 ]
He, Junling [1 ]
He, Jiawei [1 ]
Hu, Zujian [1 ]
Xu, Haibin [1 ]
机构
[1] Hangzhou Hosp Tradit Chinese Med, Dept Breast Surg, Hangzhou, Zhejiang, Peoples R China
[2] First Peoples Hosp Xiaoshan Dist, Dept Cardiol, Hangzhou, Zhejiang, Peoples R China
来源
MEDICAL SCIENCE MONITOR | 2020年 / 26卷
关键词
Breast Neoplasms; Marital Status; Prognosis; SEER Program; PSYCHOLOGICAL DISTRESS; CANCER; SURVIVAL; RISK; SPOUSES; HISTORY; STAGE;
D O I
10.12659/MSM.923630
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: The effects of marital status on infiltrating ductal carcinoma of breast cancer (IDC) have not been studied in detail. This study investigated the impact of marital status on IDC patients. Material/Methods: SEER databases were searched from 2010 to 2015 for subjects who were married, divorced, single, and wid- owed. The influence of marital status on breast cancer-specific survival (BCSS) and overall survival (OS) of IDC patients was investigated through multivariate Cox regression analysis and Kaplan-Meier analysis. To prevent bias, propensity score matching (PSM) analysis was performed. Results: The 5-year OS was 89.6%in married patients, 84.9% in divorced patients, 83.5% in single patients, and 71.3% in widowed patients (p<0.001). The 5-year BCSS were 92.9%, 90.2%, 87.6%, and 86.4%, respectively (p<0.001). Multivariate Cox regression analysis revealed that marriage was a protective factor for patients with IDC in terms of OS (divorced: HR, 1.27; 95% CI, 1.21-1.32; p<0.001; single: HR, 1.36; 95% CI, 1.31-1.42; p<0.001; widowed: HR, 1.42; 95% CI, 1.36-1.48; p<0.001) and BCSS (divorced: HR, 1.15; 95% CI, 1.09-1.21; p<0.001; single: HR, 1.27; 95% CI, 1.21-1.33; p<0.001; widowed: HR, 1.32; 95% CI, 1.25-1.40; p<0.001). Following subgroup and PSM analysis, married patients were shown to have better OS and BCSS as opposed to divorced, single, or widowed patients. Conclusions: We identify marital status as a predictor of survival in those with IDC. Widowed patients showed the highest mortality risk.
引用
收藏
页数:16
相关论文
共 50 条
  • [41] Clinicopathological characteristics, molecular landscape, and biomarker landscape for predicting the efficacy of PD-1/PD-L1 inhibitors in Chinese population with mismatch repair deficient urothelial carcinoma: a real-world study
    Ma, Yu-Ting
    Hua, Fang
    Zhong, Xiu-Ming
    Xue, Ying-Jie
    Li, Jia
    Nie, Yi-Cong
    Zhang, Xue-Dong
    Ma, Ji-Wei
    Lin, Cun-Hu
    Zhang, Hao-Zhuang
    He, Wei
    Sha, Dan
    Zhao, Miao-Qing
    Yao, Zhi-Gang
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [42] Safety and Efficacy of Second-Line TKI Plus Anti-PD1 in Metastatic Non-Clear Cell Renal Cell Carcinoma: A Real-World Study
    Huang, Tingxuan
    Wang, Jun
    Liu, Ruiqi
    Wei, Wensu
    Liu, Yang
    Zhang, Zhiling
    Guo, Shengjie
    Han, Hui
    Zhou, Fangjian
    He, Liru
    Dong, Pei
    CLINICAL GENITOURINARY CANCER, 2024, 22 (02) : 252 - 260.e3
  • [43] Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study
    Quek, Ruben G. W.
    Mardekian, Jack
    ADVANCES IN THERAPY, 2019, 36 (03) : 708 - 720
  • [44] S-1-based concurrent chemoradiotherapy plus nimotuzumab in patients with locally advanced esophageal squamous cell carcinoma who failed neoadjuvant therapy: a real-world prospective study
    Wang, Xin
    Feng, Guojie
    Yang, Xiongtao
    Yu, Nuo
    Zheng, Ziyu
    Li, Jiao
    Kang, Xiaozheng
    Chen, Xiankai
    Zhang, Ruixiang
    Li, Yong
    Wang, Zhen
    Deng, Lei
    Zhang, Tao
    Liu, Wenyang
    Wang, Jianyang
    Wang, Wenqing
    Feng, Qinfu
    Xiao, Zefen
    Zhou, Zongmei
    Bi, Nan
    Li, Yin
    Qin, Jianjun
    CANCER BIOLOGY & THERAPY, 2024, 25 (01)
  • [45] The influence of PD-L1 genetic variation on the prognosis of R0 resection colorectal cancer patients received capecitabine-based adjuvant chemotherapy: a long-term follow-up, real-world retrospective study
    Su, Jinsong
    Dai, Baiyun
    Yuan, Weitang
    Wang, Guixian
    Zhang, Zhiyong
    Li, Zhen
    Liu, Jinbo
    Song, Junmin
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (05) : 969 - 978
  • [46] Real-world effectiveness and safety of RC48-ADC alone or in combination with PD-1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: A multicenter, retrospective clinical study
    Xu, Jingwei
    Zhang, Hongqiao
    Zhang, Li
    Chu, Xiufeng
    Li, Yu
    Li, Guangyuan
    Nie, Caiyun
    Wang, Meng
    Guo, Yanwei
    CANCER MEDICINE, 2023, 12 (23): : 21159 - 21171
  • [47] Tumor-infiltrating lymphocytes (TILs) status, programmed death-ligand 1 (PD-L1) expression, and clinicopathological features of 41 cases of pure apocrine carcinoma of the breast: a retrospective study based on clinical pathological analysis and different immune statuses
    Xiao, Xuexue
    Jin, Su
    Zhangyang, Geling
    Xiao, Shiwei
    Na, Fang
    Yue, Junqiu
    GLAND SURGERY, 2022, 11 (06) : 1037 - 1046
  • [48] Hepatitis B virus infection does not affect the clinical outcome of anti-programmed death receptor-1 therapy in advanced solid malignancies Real-world evidence from a retrospective study using propensity score matching
    Zhong, Liting
    Zhong, PinShun
    Liu, Huafeng
    Li, Zelei
    Nie, Qihong
    Peng, Weiwei
    MEDICINE, 2021, 100 (49)
  • [49] Prognostic factors and adjuvant systemic therapy for patients with HER2-positive T1N0 breast cancer: evidence from a real-world study with long-term follow-up
    Gao, Song-lin
    Wang, Ding-yuan
    Wang, Xi
    Zhang, Bo
    Du, Feng
    Ju, Jie
    Yue, Jian
    Kang, Yi-kun
    Wang, Xue
    Xu, Bing-he
    Yuan, Peng
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 197 (03) : 569 - 582
  • [50] The influence of PD-L1 genetic variation on the prognosis of R0 resection colorectal cancer patients received capecitabine-based adjuvant chemotherapy: a long-term follow-up, real-world retrospective study
    Jinsong Su
    Baiyun Dai
    Weitang Yuan
    Guixian Wang
    Zhiyong Zhang
    Zhen Li
    Jinbo Liu
    Junmin Song
    Cancer Chemotherapy and Pharmacology, 2020, 85 : 969 - 978